Skip to main content
Equibles
TNDM logo

TNDM · Tandem Diabetes Care Inc · Metrics

Track TNDM — free

Use TNDM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TNDM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$16.35 -0.17 (-1.03%) At close · Oct 21
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.16B
Shares
69.58M
Volume · Oct 21 1.53M Avg daily vol (3M) 2.03M

TNDM metrics

90 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$16.35
Market cap
$1.16B

Price action

20 metrics
Price change (1W)
-0.8%
Price change (30D)
-6.2%
Price change (3M)
-6.1%
Price change (6M)
-17.5%
Price change (YTD)
-24.8%
Price change (1Y)
+6.3%
Trailing year
Price change (5Y)
-87.0%
52-week high
$28.26
52-week low
$12.82
Change from 52-week high
-41.5%
Change from 52-week low
+28.9%
Annualized volatility
76.6%
Annualized volatility (3M)
61.2%
Beta
1.0
RSI (14D)
46.2
Price vs SMA 50
-12.0%
Price vs SMA 200
-13.4%
Avg volume (3M)
2.04M
Relative volume
0.8
Average dollar volume
$37.93M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
69.58M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.2×
reciprocal yield 81.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.1×
reciprocal yield 91.4%
P / book
8.7
reciprocal yield 11.4%
FCF yield
-2.3%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-5.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.7×
reciprocal yield 59.2%
EV / revenue historical average (5Y)
2.5×
reciprocal yield 39.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
56.0%
Operating margin
-4.4%
Trailing 12 months
Net margin
-6.1%
Gross profit (TTM)
$583.32M
Operating profit (TTM)
−$45.80M
Net income (TTM)
−$63.31M
Trailing 12 months
Diluted EPS (TTM)
$-0.93
FCF margin
-2.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$15.26
Gross profit per diluted share (TTM)
$8.55
Operating profit per diluted share (TTM)
$-0.67
EBITDA per diluted share (TTM)
$-0.41
Net income per diluted share (TTM)
$-0.93
Operating cash flow per diluted share (TTM)
$-0.07
Free cash flow per diluted share (TTM)
$-0.38
Capital expenditures per diluted share (TTM)
$0.31
R&D per diluted share (TTM)
$2.75
Stock compensation per diluted share (TTM)
$1.07
Book value per share
$2.27

Growth

11 metrics
Revenue growth YoY
+5.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.04B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.9%
Year over year · more shares
Revenue CAGR (3Y)
+8.2%
Revenue CAGR (5Y)
+15.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-48.6%
Return on assets
-5.5%
Debt / equity
4.6
Current ratio
3.2
EBITDA (TTM)
−$27.83M
Free cash flow (TTM)
−$26.62M
Quick ratio
2.6
Interest coverage
-5.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$146.58M
Latest balance sheet
Cash & equivalents
$62.82M
Total assets
$1.15B
Total debt
$602.58M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$5.52M
Capital expenditures (TTM)
$21.09M
R&D (TTM)
$187.75M
SG&A (TTM)
$441.37M
Stock compensation (TTM)
$72.65M
R&D / revenue
18.0%
Stock compensation / revenue
7.0%

Ownership (13F)

9 metrics
13F filers
275
13F filer change QoQ
-2
Institutional ownership
122.2%
Conviction holders (share of 13F filers)
0.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+1.9%
Holder tenure
10.8
Price vs estimated holder cost
-32.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
28.4%

Short interest

3 metrics
Short interest
19.2%
Latest settlement · 5.3 days to cover
Days to cover
5.3d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1438133 CUSIP 875372203 13F (30d) 26 filings 25 filers Visit website Investor relations